53.45
+1.69(+3.27%)
Currency In CNY
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
3702
First IPO Date
July 14, 2017
| Name | Title | Pay | Year Born |
| Ms. Qian Xu | Director of Legal Affairs, General Counsel, Deputy GM & Secretary | 0 | 1984 |
| Mr. Lijian Zhao | GM & Director | 0 | 1976 |
| Mr. Ning Li | Deputy GM & Director | 0 | 1981 |
| Mr. Zhu Shida | Deputy GM & Non Independent Director | 0 | 1987 |
| Hui Liu | Head of the accounting department & Accounting Supervisor | 0 | N/A |
| Mr. Yujue Wang | Chief Financial Officer, Deputy GM & Non Independent Director | 0 | 1978 |
| Mr. Hao Li | Deputy GM and Head of Marketing Center & i99 Division | 0 | 1982 |
| Mr. Weijun Chen | Deputy General Manager | 0 | 1972 |
BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.